Renata Ferrarotto1, Robert Cardnell1, Shirley Su2, Lixia Diao3, A Karina Eterovic4, Victor Prieto5, William H Morrisson6, Jing Wang3, Merrill S Kies1, Bonnie S Glisson1, Lauren Averett Byers1, Diana Bell5. 1. Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Bioinformatics, University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Department of System Biology, University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: Patients with metastatic Merkel cell carcinoma are treated similarly to small cell lung cancer (SCLC). Poly ADP-ribose polymerase-1 (PARP1) is overexpressed in SCLC and response to PARP inhibitors have been reported in patients with SCLC. Our study explores PARP as a therapeutic target in Merkel cell carcinoma. METHODS: We evaluated PARP1 expression and Merkel cell polyomavirus (MCPyV) in 19 patients with Merkel cell carcinoma. Target exome-sequencing was performed in 14 samples. Sensitivity to olaparib was tested in 4 Merkel cell carcinoma cell lines. RESULTS: Most Merkel cell carcinomas (74%) express PARP1 at high levels. Mutations in DNA-damage repair genes were identified in 9 samples (64%), occurred exclusively in head neck primaries, and correlated with TP53/RB1 mutations. The TP53/RB1 mutations were more frequent in MCPyV-negative tumors. Sensitivity to olaparib was seen in the Merkel cell carcinoma line with highest PARP1 expression. CONCLUSION: Based on PARP1 overexpression, DNA-damage repair gene mutations, platinum sensitivity, and activity of olaparib in a Merkel cell carcinoma line, clinical trials with PARP inhibitors are warranted in Merkel cell carcinoma.
BACKGROUND:Patients with metastatic Merkel cell carcinoma are treated similarly to small cell lung cancer (SCLC). Poly ADP-ribose polymerase-1 (PARP1) is overexpressed in SCLC and response to PARP inhibitors have been reported in patients with SCLC. Our study explores PARP as a therapeutic target in Merkel cell carcinoma. METHODS: We evaluated PARP1 expression and Merkel cell polyomavirus (MCPyV) in 19 patients with Merkel cell carcinoma. Target exome-sequencing was performed in 14 samples. Sensitivity to olaparib was tested in 4 Merkel cell carcinoma cell lines. RESULTS: Most Merkel cell carcinomas (74%) express PARP1 at high levels. Mutations in DNA-damage repair genes were identified in 9 samples (64%), occurred exclusively in head neck primaries, and correlated with TP53/RB1 mutations. The TP53/RB1 mutations were more frequent in MCPyV-negative tumors. Sensitivity to olaparib was seen in the Merkel cell carcinoma line with highest PARP1 expression. CONCLUSION: Based on PARP1 overexpression, DNA-damage repair gene mutations, platinum sensitivity, and activity of olaparib in a Merkel cell carcinoma line, clinical trials with PARP inhibitors are warranted in Merkel cell carcinoma.
Authors: Shakuntala H Mauzo; Renata Ferrarotto; Diana Bell; Carlos A Torres-Cabala; Michael T Tetzlaff; Victor G Prieto; Phyu P Aung Journal: J Clin Pathol Date: 2016-01-27 Impact factor: 3.411
Authors: Triparna Sen; Pan Tong; C Allison Stewart; Sandra Cristea; Aly Valliani; David S Shames; Abena B Redwood; You Hong Fan; Lerong Li; Bonnie S Glisson; John D Minna; Julien Sage; Don L Gibbons; Helen Piwnica-Worms; John V Heymach; Jing Wang; Lauren Averett Byers Journal: Cancer Res Date: 2017-05-10 Impact factor: 12.701
Authors: Stephen Q Wong; Kelly Waldeck; Ismael A Vergara; Jan Schröder; Jason Madore; James S Wilmott; Andrew J Colebatch; Ricardo De Paoli-Iseppi; Jason Li; Richard Lupat; Timothy Semple; Gisela Mir Arnau; Andrew Fellowes; J Helen Leonard; George Hruby; Graham J Mann; John F Thompson; Carleen Cullinane; Meredith Johnston; Mark Shackleton; Shahneen Sandhu; David D L Bowtell; Ricky W Johnstone; Stephen B Fox; Grant A McArthur; Anthony T Papenfuss; Richard A Scolyer; Anthony J Gill; Rodney J Hicks; Richard W Tothill Journal: Cancer Res Date: 2015-12-01 Impact factor: 12.701
Authors: Robert J Cardnell; Ying Feng; Lixia Diao; You-Hong Fan; Fatemah Masrorpour; Jing Wang; Yuqiao Shen; Gordon B Mills; John D Minna; John V Heymach; Lauren A Byers Journal: Clin Cancer Res Date: 2013-09-27 Impact factor: 12.531
Authors: Travis E Grotz; Tina I Tarantola; Clark C Otley; Amy L Weaver; Michaela E McGree; James W Jakub Journal: Ann Surg Oncol Date: 2012-03-28 Impact factor: 5.344
Authors: Kaja Milanowska; Joanna Krwawicz; Grzegorz Papaj; Jan Kosinski; Katarzyna Poleszak; Justyna Lesiak; Ewelina Osinska; Kristian Rother; Janusz M Bujnicki Journal: Nucleic Acids Res Date: 2010-11-04 Impact factor: 16.971
Authors: C Allison Stewart; Pan Tong; Robert J Cardnell; Triparna Sen; Lerong Li; Carl M Gay; Fatemah Masrorpour; You Fan; Rasha O Bara; Ying Feng; Yuanbin Ru; Junya Fujimoto; Samrat T Kundu; Leonard E Post; Karen Yu; Yuqiao Shen; Bonnie S Glisson; Ignacio Wistuba; John V Heymach; Don L Gibbons; Jing Wang; Lauren Averett Byers Journal: Oncotarget Date: 2017-04-25
Authors: Hannah Farmer; Nuala McCabe; Christopher J Lord; Andrew N J Tutt; Damian A Johnson; Tobias B Richardson; Manuela Santarosa; Krystyna J Dillon; Ian Hickson; Charlotte Knights; Niall M B Martin; Stephen P Jackson; Graeme C M Smith; Alan Ashworth Journal: Nature Date: 2005-04-14 Impact factor: 69.504
Authors: Gerald Goh; Trent Walradt; Vladimir Markarov; Astrid Blom; Nadeem Riaz; Ryan Doumani; Krista Stafstrom; Ata Moshiri; Lola Yelistratova; Jonathan Levinsohn; Timothy A Chan; Paul Nghiem; Richard P Lifton; Jaehyuk Choi Journal: Oncotarget Date: 2016-01-19
Authors: Elena Dellambra; Maria Luigia Carbone; Francesca Ricci; Francesco Ricci; Francesca Romana Di Pietro; Gaia Moretta; Sofia Verkoskaia; Elisa Feudi; Cristina M Failla; Damiano Abeni; Luca Fania Journal: Biomedicines Date: 2021-06-23